- Interferon-gamma release assays (IGRAs) are blood tests used to detect latent tuberculosis infection (LTBI) by measuring the immune system's response to Mycobacterium tuberculosis-specific antigens. They serve as alternatives to the traditional Tuberculin Skin Test (TST)
- The demand for IGRAs is significantly driven by the rising global burden of tuberculosis, growing awareness regarding latent TB detection, and the need for accurate, quick diagnostics, especially in low- and middle-income countries
- North America is expected to dominate the interferon-gamma release assays (IGRAs)s market with a market share of 40.5%, due to widespread adoption of advanced TB diagnostics, strong public health infrastructure, and supportive reimbursement policies
- Asia-Pacific is expected to be the fastest growing region in the interferon-gamma release assays (IGRAs) market with a market share of 25.5%, during the forecast period due to increasing TB prevalence, rising healthcare investment, and greater awareness of latent TB screening
- Latent tuberculosis infection (LTBI) detection segment is expected to dominate the market with a market share of 60.5% due to its increasing global focus on early TB detection and prevention strategies
